The Future of Vestibular Schwannoma Management

Lindsay Scott Moore; Konstantina M Stankovic

doi:10.1016/j.otc.2023.02.018

The Future of Vestibular Schwannoma Management

Otolaryngol Clin North Am. 2023 Jun;56(3):611-622. doi: 10.1016/j.otc.2023.02.018. Epub 2023 Apr 3.

Authors

Lindsay Scott Moore¹, Konstantina M Stankovic²

Affiliations

¹ Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Palo Alto, CA 94304, USA.
² Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Palo Alto, CA 94304, USA; Department of Neurosurgery, Stanford University School of Medicine, 453 Quarry Road, Palto Alto, CA 94304, USA. Electronic address: kstankovic@stanford.edu.

PMID: 37019772
DOI: 10.1016/j.otc.2023.02.018

Abstract

The future of the management of both sporadic and neurofibromatosis type 2-asscoiated vestibular schwannomas (VSs) will be shaped by cutting-edge technologic and biomedical advances to enable personalized, precision medicine. This scoping review envisions the future by highlighting the most promising developments published, ongoing, planned, or potential that are relevant for VS, including integrated omics approaches, artificial intelligence algorithms, biomarkers, liquid biopsy of the inner ear, digital medicine, inner ear endomicroscopy, targeted molecular imaging, patient-specific stem cell-derived models, ultra-high dose rate radiotherapy, optical imaging-guided microsurgery, high-throughput development of targeted therapeutics, novel immunotherapeutic strategies, tumor vaccines, and gene therapy.

Keywords: Adoptive cell therapy; Biomarkers; Fluorescence-guided surgery; Gene therapy; Human induced pluripotent stem cell models (hiPSC); Immunotherapy; Neurofibromatosis type 2 (NF2); Vestibular schwannoma.

Publication types

Review

MeSH terms

Algorithms
Artificial Intelligence
Ear, Inner* / pathology
Humans
Neurofibromatosis 2*
Neuroma, Acoustic* / therapy